Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 28, 2020; 26(44): 6993-7004
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.6993
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.6993
Table 2 Ongoing treatment of inflammatory bowel disease patients from a referral center
| Medicaments | IBD, n (%) | CD, n (%) | UC, n (%) |
| Sulfasalazine | 63 | 10 (8.7) | 53 (28.5) |
| Oral Mesalazine | 102 | 7 (6.1) | 95 (51.1) |
| Topic Mesalazine | 125 | 125 (67.2) | |
| Azathioprine | 70 | 42 (36.5) | 28 (15.1) |
| Azathioprine + Anti-TNFα | 31 | 28 (24.3) | 3 (1.6) |
| Methotrexate + Anti-TNFα | 3 | 3 (2.6) | |
| Anti-TNF α | 30 | 29 (25.2) | 1 (0.5) |
| Corticoid | 2 | 2 (1.7) |
- Citation: Fortes FML, Boa Sorte N, Mariano VD, Andrade LD, Oliveira FA, Santos MCA, dos Santos CIN, Passos CA, Pacheco MP, Surlo VC, de Almeida NP, Fontes JAM, Pimentel AM, Rocha R, Santana GO. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America. World J Gastroenterol 2020; 26(44): 6993-7004
- URL: https://www.wjgnet.com/1007-9327/full/v26/i44/6993.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i44.6993